Pharmacogenetics in rheumatology: The prospects and limitations of an emerging field

Rheumatology

Volumn 41, Issue 11, 2002, Pages 1273-1279

  Siva, C ^a   Yokoyama, W M ^a   McLeod, H L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Lupus; Pharmacogenetics; Pharmacogenomics; Polymorphism; Rheumatic diseases; Rheumatic drugs; Rheumatology

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CODEINE; DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; HYDROCODONE; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; OXYCODONE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TRAMADOL;

ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MEDLINE; PATHOGENESIS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOLOGY; RISK ASSESSMENT; SEQUENCE HOMOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANALGESICS, OPIOID; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; DRUG DESIGN; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; FORECASTING; GENETICS, POPULATION; HUMANS; MALE; METHOTREXATE; PHARMACOGENETICS; RHEUMATIC DISEASES; RHEUMATOLOGY; RISK ASSESSMENT; UNITED STATES;

EID: 0036851446     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487-91.
2. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
3. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 2001;29:1205-9.
4. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-65.
5. McLeod HL, Evans WE. Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2000;41:101-21.
6. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. Q J Med 2000;93:391-423.
7. Astbury C. Pharmacogenetics: what role in rheumatology? Br J Rheumatol 1994;33:1100-1.
8. Waring RH, Emery P. The genetic basis of response to drugs-a rheumatological perspective. Br J Rheumatol 1993;32:181-8.
9. Strandberg I, Boman G, Hassler L, Sjoqvist F. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand 1976;200:367-71.
10. Baer AL, Woosley RL, Pincus T. Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. Arthritis Rheum 1986; 29:508-14.
11. Gaffney PM, Moser KL, Graham RR, Behrens TW. Recent advances in the genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 2002;28:111-26.
12. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810-6.
13. Krynetski EY, Evans WE. Genetic polymorphisms of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000;61:136-46.
14. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphisms of thiopurine methyltransferase and its clinical relevance for childhood lymphoblastic leukemia. Leukemia 2000;14:567-72.
15. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716-8.
16. Evans WE, Hon YY, B, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.
17. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55:15-20.
18. Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 2001;51:475-7.
19. Kumagai K, Hiyama K, Ishioka S et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001; 11:275-8.
20. Collie-Duguid ES, Pritchard SC, Powrie RH et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
21. Kerstens PJSM, Stolk JN, DeAbreu RA, Lambooy LHJ, Van de Putte LBA, Boerbooms A. Azathioprine related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:142-5.
22. Stolk JN, Boerbooms AT, De Abreu RA et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1858-66.
23. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999;38:640-4.
24. Tavadia S, Mydlarski PR, Reis MD et al. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42:628-32.
25. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
26. McLeod HL, Siva C. The thiopurine s-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002;3:89-98.
27. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine s-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
28. Weber WW. Populations and genetic polymorphisms. Mol Diagn 1999;4:299-307.
29. Ingelman-Sundberg M. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics. Arch Toxicol Suppl 1997; 19:3-13.
30. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultra rapid metabolisers of debrisoquine in an Ethiopian population carrying duplicated and multi-duplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-6.
31. McClellan R, Oscarson M, Seidegard J, Evans D, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187-91.
32. Eichelbaum M, Gross A. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-94.
33. Wilcox R, Owen H. Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anesthetist. Anaesth Intensive Care 2000;28:611-9.
34. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M. Same incidence of adverse events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998;76:27-33.
35. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup S. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-44.
36. Pullar T, Hunter JA, Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 1985;44:831-7.
37. Bax DE, Greaves MS, Amos RS. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br J Rheumatol 1986;25:282-4.
38. Sabbagh N, Delaporte E, Marez D, Loguidice JM, Piette F, Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997;7:131-5.
39. van Ede AE, Laan RFJM, Blom HK, De Abreu RA, van de Putte LBA. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
40. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56:142-50.
41. van Ede AE, Laan RFJM, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene-a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
42. Blom HJ, van Riel PLCM, van't Hof MA et al. Influence of sulfasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
43. De Benedetti VMG, Biglia N, Sismondi P, De Bortoli M. DNA chips: the future of biomarkers. Int J Biol Markers 2000; 15:1-9.
44. Wilgenbus KK, Lichter P. DNA chip technology ante portas. J Mol Med 1999;77:761-8.
45. Coats AJS. Pharmacogenomics: hope or hype? Int J Cardiol 2000;76:1-3.